» Articles » PMID: 17420112

A Mathematical Approach to Study Combined Effects of Toxicants in Vitro: Evaluation of the Bliss Independence Criterion and the Loewe Additivity Model

Overview
Specialty Toxicology
Date 2007 Apr 11
PMID 17420112
Citations 73
Authors
Affiliations
Soon will be listed here.
Abstract

The study of interactions among toxicants is of fundamental interest and practical importance in toxicological sciences. However, a final agreement on the definition of agent interaction is lacking, and therefore, particular care should be adopted when using the terms additivity, synergism and antagonism, unless the exact toxicological pathways of the compounds studied are known. Two main different approaches, the Bliss independence criterion and the Loewe additivity model, have been generally used in co-exposure experiments. In some cases, they can present dramatically different results, depending on the slope of the pure dose-response curves of single substances. Here, we consider both models in in vitro experiments, where the dose-response curves can be extrapolated. Advantages and limitations of both approaches are discussed, using several mathematical simulations to better explain them, and applying the Hill function for the dose-response model curve. Overall we conclude that the Loewe additivity model is slightly preferable because of a general higher biological plausibility. However, which model to use must be determined case by case and the evaluation can be aided by experimental approaches, such as the study of multiple biomarkers and asynchronous exposures.

Citing Articles

Checkerboard synergistic data analysis using a Hill function-based approach.

Gutheil W bioRxiv. 2025; .

PMID: 39975223 PMC: 11839125. DOI: 10.1101/2025.02.05.636765.


Cellular and Molecular Evidence of the Synergistic Antitumour Effects of Hydroxytyrosol and Metformin in Prostate Cancer.

Porcel-Pastrana F, Montero-Hidalgo A, G-Garcia M, Gil-Duque I, Prats-Escribano A, Gahete M Int J Mol Sci. 2025; 26(3).

PMID: 39941109 PMC: 11818903. DOI: 10.3390/ijms26031341.


A bispecific antibody targeting EGFR and AXL delays resistance to osimertinib.

Simoni-Nieves A, Lindzen M, Giri S, Gupta N, Chatterjee R, Selvadurai B Cell Rep Med. 2024; 5(9):101703.

PMID: 39216477 PMC: 11528239. DOI: 10.1016/j.xcrm.2024.101703.


Network-driven cancer cell avatars for combination discovery and biomarker identification for DNA damage response inhibitors.

Papp O, Jordan V, Hetey S, Balazs R, Kaszas V, Bartha A NPJ Syst Biol Appl. 2024; 10(1):68.

PMID: 38906870 PMC: 11192759. DOI: 10.1038/s41540-024-00394-w.


Pharmacokinetics-Pharmacodynamics Modeling for Evaluating Drug-Drug Interactions in Polypharmacy: Development and Challenges.

Zhao D, Huang P, Yu L, He Y Clin Pharmacokinet. 2024; 63(7):919-944.

PMID: 38888813 DOI: 10.1007/s40262-024-01391-2.